TY - JOUR
T1 - Reasons for Discontinuing Active Surveillance
T2 - Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
AU - Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium
AU - Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium
AU - Van Hemelrijck, Mieke
AU - Ji, Xi
AU - Kattan, Mike W.
AU - Helleman, Jozien
AU - Roobol, Monique J.
AU - Nieboer, Daan
AU - Bangma, Chris H.
AU - van der Linden, Wim
AU - Frydenberg, Mark
AU - Rannikko, Antti
AU - Lee, Lui S.
AU - Gnanapragasam, Vincent J.
AU - Trock, Bruce
AU - Ehdaie, Behfar
AU - Carroll, Peter
AU - Filson, Christopher
AU - Kim, Jeri
AU - Logothetis, Christopher
AU - Morgan, Todd
AU - Klotz, Laurence
AU - Pickles, Tom
AU - Hyndman, Eric
AU - Moore, Caroline M.
AU - Dasgupta, Prokar
AU - Villers, Arnauld
AU - Valdagni, Riccardo
AU - Perry, Antoinette
AU - Hugosson, Jonas
AU - Rubio-Briones, Jose
AU - Bjartell, Anders
AU - Hefermehl, Lukas
AU - Lui Shiong, Lee
AU - Kakehi, Yoshiyuki
AU - Ha Chung, Byung
AU - van der Kwast, Theo
AU - Obbink, Henk
AU - Hulsen, Tim
AU - de Jonge, Cees
AU - Xinge, Ji
AU - Muir, Kenneth
AU - Lophatananon, Artitaya
AU - Fahey, Michael
AU - Steyerberg, Ewout
AU - Zhang, Liying
AU - Santa Olalla, Aida
AU - Beckmann, Kerri
AU - Denton, Brian
AU - Hayen, Andrew
AU - Boutros, Paul
AU - Guo, Wei
N1 - Funding Information:
Funding/Support and role of the sponsor : This work was supported by the Movember Foundation. The funder did not play any role in the study design, collection, analysis, or interpretation of data, or in the drafting of this paper.
Publisher Copyright:
© 2018 European Association of Urology
PY - 2019/3
Y1 - 2019/3
N2 - Background: Careful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa). Objective: Using Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation. Design, setting, and participants: We compared data from 10 296 men on AS from 21 centres across 12 countries. Outcome measurements and statistical analysis: Cumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation. Results and limitations: During 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4–28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0–13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5–2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4–2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5 yr, 4561 had follow-up for <5 yr, and 149 were lost to follow-up. Cumulative incidence of progression was 27.5% (95% CI: 26.4–28.6%) at 5 yr and 38.2% (95% CI: 36.7–39.9%) at 10 yr. A limitation is that not all centres were included due to limited information on the reason for discontinuation and limited follow-up. Conclusions: Our descriptive analyses of current AS practices worldwide showed that 43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease progression. Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to AS, which will also reduce discontinuation due to conversion to active treatment without evidence of disease progression. Patient summary: Our assessment of a worldwide database of men with prostate cancer (PCa) on active surveillance (AS) shows that 43.6% drop out of AS within 5 yr, mainly due to signs of disease progression. Better tools are needed to select and monitor men with PCa as part of AS.
AB - Background: Careful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa). Objective: Using Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation. Design, setting, and participants: We compared data from 10 296 men on AS from 21 centres across 12 countries. Outcome measurements and statistical analysis: Cumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation. Results and limitations: During 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4–28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0–13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5–2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4–2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5 yr, 4561 had follow-up for <5 yr, and 149 were lost to follow-up. Cumulative incidence of progression was 27.5% (95% CI: 26.4–28.6%) at 5 yr and 38.2% (95% CI: 36.7–39.9%) at 10 yr. A limitation is that not all centres were included due to limited information on the reason for discontinuation and limited follow-up. Conclusions: Our descriptive analyses of current AS practices worldwide showed that 43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease progression. Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to AS, which will also reduce discontinuation due to conversion to active treatment without evidence of disease progression. Patient summary: Our assessment of a worldwide database of men with prostate cancer (PCa) on active surveillance (AS) shows that 43.6% drop out of AS within 5 yr, mainly due to signs of disease progression. Better tools are needed to select and monitor men with PCa as part of AS.
UR - http://www.scopus.com/inward/record.url?scp=85055553741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055553741&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2018.10.025
DO - 10.1016/j.eururo.2018.10.025
M3 - Article
C2 - 30385049
AN - SCOPUS:85055553741
VL - 75
SP - 523
EP - 531
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 3
ER -
